

Appl. No. : 10/817,591  
Filed : April 2, 2004

*please, enter  
Feb. 28, 2007*

### AMENDMENTS TO THE CLAIMS

1-35. (Canceled)

36. (Currently amended) A method of increasing the titer of hepatitis viral antigen-specific IgG antibodies in a subject in need thereof ~~comprising~~ consisting essentially of:

identifying a subject in need of an increase in titer of IgG antibodies that are specific for a hepatitis viral antigen; and

providing, in a single administration, ~~said subject~~ an immunogenic composition that comprising comprises an effective amount of ribavirin and a nucleic acid molecule encoding said hepatitis viral antigen to said subject.

37. (Cancelled)

38. (Currently amended) The method of Claim ~~37~~36, wherein said hepatitis antigen is an antigen from ~~hepatitis A virus~~, hepatitis B virus; or hepatitis C virus.

39. (Currently amended) The method of Claim 38, wherein said viral antigen is comprises a hepatitis C viral antigen.

40. (Currently amended) The method of Claim 39, wherein said viral antigen is comprises an NS3 antigen.

41. (Currently amended) The method of Claim 39, wherein said viral antigen is comprises an NS4A antigen.

42-50. (Cancelled)

51. (Currently amended) A method of enhancing a T cell response to a hepatitis viral antigen in a subject in need thereof ~~comprising~~ consisting essentially of:

identifying a subject in need of an improvement in a T cell response to a hepatitis viral antigen; and

providing, in a single administration, ~~said subject~~ an immunogenic composition ~~comprising~~ that comprises an effective amount of ribavirin and a nucleic acid molecule encoding said viral antigen to said subject.

52. (Cancelled)

53. (Currently amended) The method of Claim ~~52~~51, wherein said hepatitis antigen is an antigen from ~~hepatitis A virus~~, hepatitis B virus; or hepatitis C virus.

Appl. No. : 10/817,591  
Filed : April 2, 2004

54. (Currently amended) The method of Claim 53, wherein said viral antigen is comprises a hepatitis C viral antigen.

55. (Currently amended) The method of Claim 54, wherein said viral antigen is comprises an NS3 antigen.

56. (Currently amended) The method of Claim 54, wherein said viral antigen is comprises an NS4A antigen.

57-81. (Cancelled)

82. (Previously presented) The method of Claim 36, wherein said nucleic acid molecule comprises SEQ ID NO: 16.

83. (Previously presented) The method of Claim 36, wherein said nucleic acid molecule consists essentially of the nucleic acid of SEQ ID NO: 16.

84. (Previously presented) The method of Claim 36, wherein said nucleic acid molecule consists of the nucleic acid of SEQ ID NO: 16.

85. (Previously presented) The method of Claim 51, wherein said nucleic acid molecule comprises SEQ ID NO: 16.

86. (Previously presented) The method of Claim 51, wherein said nucleic acid molecule consists essentially of the nucleic acid of SEQ ID NO: 16.

87. (Previously presented) The method of Claim 51, wherein said nucleic acid molecule consists of the nucleic acid of SEQ ID NO: 16.

88. (New) The method of Claim 36, wherein said immunogenic composition is provided to said subject transdermally.

89. (New) The method of Claim 36, wherein said immunogenic composition is provided to said subject intranasally.

90. (New) The method of Claim 51, wherein said immunogenic composition is provided to said subject transdermally.

91. (New) The method of Claim 51, wherein said immunogenic composition is provided to said subject intranasally.

92. (New) The method of Claim 36, wherein said immunogenic composition comprises an oil.

Appl. No. : 10/817,591  
Filed : April 2, 2004

93. (New) The method of Claim 51, wherein said immunogenic composition comprises an oil.

94. (New) The method of Claim 36, wherein said immunogenic composition is formulated for use with an injection device.

95. (New) The method of Claim 94, wherein said injection device is an electrical injection device.

96. (New) The method of Claim 94, wherein said injection device is a needleless injection device.

97. (New) The method of Claim 51, wherein said immunogenic composition is formulated for use with an injection device.

98. (New) The method of Claim 97, wherein said injection device is an electrical injection device.

99. (New) The method of Claim 97, wherein said injection device is a needleless injection device.

~~100~~ 103. (New) The method of Claim 36, wherein said nucleic acid comprises a sequence that encodes SEQ ID NO: 17.

~~101~~ 104. (New) The method of Claim 36, wherein said nucleic acid consists essentially of a sequence that encodes SEQ ID NO: 17.

~~102~~ 105. (New) The method of Claim 36, wherein said nucleic acid consists of a sequence that encodes SEQ ID NO: 17.

~~103~~ 106. (New) The method of Claim 51, wherein said nucleic acid comprises a sequence that encodes SEQ ID NO: 17.

~~104~~ 107. (New) The method of Claim 51, wherein said nucleic acid consists essentially of a sequence that encodes SEQ ID NO: 17.

~~105~~ 108. (New) The method of Claim 51, wherein said nucleic acid consists of a sequence that encodes SEQ ID NO: 17.